INTECH Investment Management’s Allogene Therapeutics ALLO Stock Holding History

INTECH Investment Management’s Portfolio ALLO Stock Details ALLO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$118K	Buy	56,520 +13,459	+31%	+$29.6K	﹤0.01%	1916
2026 Q1	$105K	Sell	43,061 -43,576	-50%	-$87.3K	﹤0.01%	1887
2025 Q4	$119K	Buy	86,637 +14,742	+21%	+$19.4K	﹤0.01%	2124
2025 Q3	$89.2K	Sell	71,895 -26,776	-27%	-$31.9K	﹤0.01%	2292
2025 Q2	$111K	Sell	98,671 -21,687	-18%	-$28.8K	﹤0.01%	2269
2025 Q1	$176K	Buy	120,358 +49,035	+69%	+$92.4K	﹤0.01%	2141
2024 Q4	$152K	Buy	71,323 +29,992	+73%	+$74K	﹤0.01%	2111
2024 Q3	$116K	Buy	+41,331	New	+$110K	﹤0.01%	1863

Other funds holding ALLO

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Pfizer New York $170M AUM 191.09% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return

SCM

Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

INTECH Investment Management's ALLO Position: Q2 2026 in Review

INTECH Investment Management increased its Allogene Therapeutics (ALLO) stake by 31% in Q2 2026, buying an estimated $29.6K and bringing the position to 56,520 shares worth $118K. The position accounts for ﹤0.01% of the portfolio, ranked #1916.

INTECH Investment Management first reported a position in ALLO in Q3 2024 and has held it in 8 quarters since. The position peaked at $176K in Q1 2025. 209 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.

INTECH Investment Management held 56,520 shares of Allogene Therapeutics worth $118K as of Q2 2026.
INTECH Investment Management bought 13,459 Allogene Therapeutics shares in Q2 2026, an estimated $29.6K.
Allogene Therapeutics made up ﹤0.01% of INTECH Investment Management's portfolio in Q2 2026, its #1916 holding.
INTECH Investment Management first reported a position in Allogene Therapeutics in Q3 2024 and has held it in 8 quarters since.
INTECH Investment Management's Allogene Therapeutics position peaked at $176K in Q1 2025.
209 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.

Based on INTECH Investment Management's 13F filing for Q2 2026, filed 10 Aug 2026.